NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $54.75 +0.06 (+0.11%) (As of 09/11/2024 ET) Add Compare Share Share Today's Range$53.60▼$55.2050-Day Range$41.68▼$54.7552-Week Range$27.02▼$73.00Volume289,765 shsAverage Volume373,756 shsMarket Capitalization$1.98 billionP/E RatioN/ADividend YieldN/APrice Target$92.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Keros Therapeutics alerts: Email Address Keros Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside68.3% Upside$92.17 Price TargetShort InterestBearish9.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 5 Articles This WeekInsider TradingSelling Shares$11 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.78) to ($5.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector577th out of 911 stocksPharmaceutical Preparations Industry261st out of 423 stocks 3.5 Analyst's Opinion Consensus RatingKeros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKeros Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Keros Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.67% of the outstanding shares of Keros Therapeutics have been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Keros Therapeutics has recently increased by 10.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KROS. Previous Next 2.0 News and Social Media Coverage News SentimentKeros Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Keros Therapeutics this week, compared to 2 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,002,500.00 in company stock.Percentage Held by Insiders22.90% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($4.78) to ($5.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Keros Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTrader Books $13M Profit on “Nvidia of Crypto”A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips.Click here to review my research and the strategy I've developed for the opportunity to trade this c About Keros Therapeutics Stock (NASDAQ:KROS)Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More KROS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KROS Stock News HeadlinesAugust 16, 2024 | insidertrades.comKeros Therapeutics, Inc. (NASDAQ:KROS) Director Carl L. Gordon Sells 250,000 SharesSeptember 12 at 2:03 AM | americanbankingnews.comAnalysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $92.17September 12, 2024 | Crypto 101 Media (Ad)Trader Books $13M Profit on “Nvidia of Crypto”A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips.September 5, 2024 | markets.businessinsider.comKeros Therapeutics (KROS) Receives a Buy from Truist FinancialSeptember 4, 2024 | markets.businessinsider.comKeros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS TrialAugust 28, 2024 | globenewswire.comKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesAugust 9, 2024 | markets.businessinsider.comStrong Financials and Promising Clinical Trials Bolster Buy Rating for Keros TherapeuticsAugust 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics as KER-065 Shows Promise in Obesity and Neuromuscular DisordersSeptember 12, 2024 | Crypto 101 Media (Ad)Trader Books $13M Profit on “Nvidia of Crypto”A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips.August 7, 2024 | globenewswire.comKeros Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 1, 2024 | finance.yahoo.comKeros Therapeutics, Inc. (KROS)June 25, 2024 | benzinga.comAnalyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech GrowthJune 17, 2024 | globenewswire.comKeros Therapeutics Announces Leadership UpdatesJune 17, 2024 | globenewswire.comKeros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationJune 10, 2024 | seekingalpha.comKeros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood CancersMay 28, 2024 | globenewswire.comKeros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsMay 21, 2024 | investing.comKeros Therapeutics Inc (KROS)May 14, 2024 | globenewswire.comKeros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationSee More Headlines Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/12/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KROS CUSIPN/A CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$92.17 High Stock Price Target$105.00 Low Stock Price Target$60.00 Potential Upside/Downside+68.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,990,000.00 Net Margins-62,012.55% Pretax Margin-62,012.55% Return on Equity-44.73% Return on Assets-41.06% Debt Debt-to-Equity RatioN/A Current Ratio20.37 Quick Ratio20.37 Sales & Book Value Annual Sales$271,000.00 Price / Sales7,290.03 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book4.94Miscellaneous Outstanding Shares36,084,000Free Float27,821,000Market Cap$1.98 billion OptionableOptionable Beta1.22 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Jasbir S. Seehra Ph.D. (Age 68)President, CEO & Director Comp: $1.13MMr. Keith C. Regnante MBA (Age 54)Chief Financial Officer Comp: $636.11kMr. Christopher Rovaldi M.Sc. (Age 49)Chief Operating Officer Comp: $784.9kMs. Esther Cho J.D.Senior VP, General Counsel & SecretaryMs. Robin WagnerSenior Vice President of Human ResourcesMr. John Oram M.B.A.Senior Vice President of Program & Portfolio ManagementMore ExecutivesKey CompetitorsSierra OncologyNASDAQ:SRRADicerna PharmaceuticalsNASDAQ:DRNAScholar RockNASDAQ:SRRKY-mAbs TherapeuticsNASDAQ:YMABAmarinNASDAQ:AMRNView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 84,810 shares on 8/20/2024Ownership: 1.050%Point72 Asset Management L.P.Sold 601,531 shares on 8/19/2024Ownership: 1.026%Algert Global LLCBought 1,505 shares on 8/16/2024Ownership: 0.044%The Manufacturers Life Insurance Company Bought 2,517 shares on 8/15/2024Ownership: 0.047%Point72 Asia Singapore Pte. Ltd.Bought 2,811 shares on 8/15/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $39.76 at the beginning of 2024. Since then, KROS stock has increased by 37.7% and is now trading at $54.75. View the best growth stocks for 2024 here. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.02. The business had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative trailing twelve-month return on equity of 44.73% and a negative net margin of 62,012.55%. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $75 million in an initial public offering on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Top institutional investors of Keros Therapeutics include Darwin Global Management Ltd. (4.23%), Candriam S.C.A. (1.22%), Nantahala Capital Management LLC (1.05%) and Point72 Asset Management L.P. (1.03%). Insiders that own company stock include Jennifer Lachey, Christopher Rovaldi, Keith Regnante and Julius Knowles. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA) and Karyopharm Therapeutics (KPTI). This page (NASDAQ:KROS) was last updated on 9/12/2024 by MarketBeat.com Staff From Our PartnersInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredYour Ticket to the Future $75B Air Mobility Market Boom?Looking for the next big investment opportunity? This company could be your chance to catch the electric aviat...Market JAR | SponsoredHow you could collect “AI Royalties” from NVIDIA, META and TSMC...If you've missed out on the first wave of big AI winners... Don't worry. Because there's a much better -...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRecently listed NASDAQ firm is well positioned for growth with game-changing AI platform for e-commerce.With an innovative AI platform, one tiny but growing NASDAQ firm is ushering in a new e-commerce era and is tr...Smallcaps Daily | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
